Advertisement

The Rise and Fall of β-Agonists in the Treatment of ARDS

  • C. R. Bassford
  • D. R. Thickett
  • G. D. Perkins
Part of the Annual Update in Intensive Care and Emergency Medicine book series (AUICEM, volume 2012)

Abstract

The acute respiratory distress syndrome (ARDS) is a severe inflammatory condition of the lung, which can be triggered by a number of different pulmonary and extra-pulmonary insults [1]. The characteristic pathological changes of ARDS include an exudative phase, with the accumulation of fluid within the lung, the release of pro-inflammatory cytokines and infiltration of inflammatory cells, especially neutrophils, into the lung parenchyma. Damage to the alveolar epithelium and pulmonary capillary endothelium occur and patients develop the characteristic histological appearance of diffuse alveolar damage [1]. This manifests clinically as non-cardiogenic pulmonary edema, which reduces lung compliance and impairs gas exchange.

Keywords

Acute Lung Injury Lactic Acidosis Respir Crit Alveolar Fluid Clearance Nebulized Salbutamol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342: 1334–1349PubMedCrossRefGoogle Scholar
  2. 2.
    Adhikari N, Burns KE, Meade MO (2004) Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev CD004477Google Scholar
  3. 3.
    The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301–1308CrossRefGoogle Scholar
  4. 4.
    Wiedemann HP, Wheeler AP, Bernard GR, et al (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354: 2564–2575PubMedCrossRefGoogle Scholar
  5. 5.
    Zambon M, Vincent JL (2008) Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 133: 1120–1127PubMedCrossRefGoogle Scholar
  6. 6.
    Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F (2004) Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome. Crit Care 8: 25–32PubMedCrossRefGoogle Scholar
  7. 7.
    Johnson M (2006) Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117: 18–24PubMedCrossRefGoogle Scholar
  8. 8.
    Mutlu GM, Factor P (2008) Alveolar epithelial beta2-adrenergic receptors. Am J Respir Cell Mol Biol 38: 127–134PubMedCrossRefGoogle Scholar
  9. 9.
    Ware LB, Matthay MA (2001) Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 163: 1376–1383PubMedCrossRefGoogle Scholar
  10. 10.
    Berthiaume Y, Matthay MA (2007) Alveolar edema fluid clearance and acute lung injury. Respir Physiol Neurobiol 159: 350–359PubMedCrossRefGoogle Scholar
  11. 11.
    Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S, Matthay MA (1997) Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med 155: 506–512PubMedCrossRefGoogle Scholar
  12. 12.
    Dumasius V, Sznajder JI, Azzam ZS, et al. (2001) β2-Adrenergic receptor overexpression increases alveolar fluid clearance and responsiveness to endogenous catecholamines in rats. Circ Res 89: 907–914PubMedCrossRefGoogle Scholar
  13. 13.
    Grommes J, Soehnlein O (2011) Contribution of neutrophils to acute lung injury. Mol Med 17: 293–307PubMedCrossRefGoogle Scholar
  14. 14.
    Perkins GD, Nathani N, McAuley DF, Gao F, Thickett DR (2007) In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax 62: 36–42PubMedCrossRefGoogle Scholar
  15. 15.
    Bloemen PG, van den Tweel MC, Henricks PA, et al (1997) Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 272: L580–L587PubMedGoogle Scholar
  16. 16.
    Maris NA, de Vos AF, Dessing MC, et al (2005) Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 172: 878–884PubMedCrossRefGoogle Scholar
  17. 17.
    Farmer P, Pugin J (2000) beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 279: L675–682PubMedGoogle Scholar
  18. 18.
    Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM (2007) Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA-and NF-kappaB-independent mechanisms. Cell Signal 19: 251–260PubMedCrossRefGoogle Scholar
  19. 19.
    Minnear FL, DeMichele MA, Moon DG, Rieder CL, Fenton JW (1989) Isoproterenol reduces thrombin-induced pulmonary endothelial permeability in vitro. Am J Physiol 257: H1613–H1623PubMedGoogle Scholar
  20. 20.
    Takashima S, Schlidt SA, Koukoulis G, Sevala M, Egan TM (2005) Isoproterenol reduces ischemia-reperfusion lung injury despite beta-blockade. J Surg Res 126: 114–120PubMedCrossRefGoogle Scholar
  21. 21.
    Perkins GD, Gao F, Thickett DR (2008) In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 63: 215–220PubMedCrossRefGoogle Scholar
  22. 22.
    Basran GS, Hardy JG, Woo SP, Ramasubramanian R, Byrne AJ (1986) Beta-2-adrenoceptor agonists as inhibitors of lung vascular permeability to radiolabelled transferrin in the adult respiratory distress syndrome in man. Eur J Nucl Med 12: 381–384PubMedCrossRefGoogle Scholar
  23. 23.
    Pesenti A, Pelosi P, Rossi N, Aprigliano M, Brazzi L, Fumagalli R (1993) Respiratory mechanics and bronchodilator responsiveness in patients with the adult respiratory distress syndrome. Crit Care Med 21: 78–83PubMedCrossRefGoogle Scholar
  24. 24.
    Wright PE, Carmichael LC, Bernard GR (1994) Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 106: 1517–1523PubMedCrossRefGoogle Scholar
  25. 25.
    Morina P, Herrera M, Venegas J, Mora D, Rodriguez M, Pino E (1997) Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Intensive Care Med 23: 58–64PubMedCrossRefGoogle Scholar
  26. 26.
    Manocha S, Gordon AC, Salehifar E, Groshaus H, Walley KR, Russell JA (2006) Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Crit Care 10: R12PubMedCrossRefGoogle Scholar
  27. 27.
    Perkins GD, McAuley DF, Thickett DR, Gao F (2006) The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 173: 281–287PubMedCrossRefGoogle Scholar
  28. 28.
    Licker M, Tschopp JM, Robert J, Frey JG, Diaper J, Ellenberger C (2008) Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 133: 845–852PubMedCrossRefGoogle Scholar
  29. 29.
    Craig TR, Duffy MJ, Shyamsundar M, et al (2010) Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury. Crit Care Med 38: 114–120PubMedCrossRefGoogle Scholar
  30. 30.
    Effros RM (2006) The beta-agonist lung injury trial (BALTI). Am J Respir Crit Care Med 173: 1290PubMedCrossRefGoogle Scholar
  31. 31.
    Matthay MA, Brower RG, Carson S, et al (2011) Randomized, placebo-controlled clinical trial of an aerosolized beta-2 agonist for treatment of acute lung injury. Am J Respir Crit Care Med 184: 561–568PubMedCrossRefGoogle Scholar
  32. 32.
    Perkins GD, Gates S, Lamb SE, McCabe C, Young D, Gao F (2011) Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: A randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials 12: 113PubMedCrossRefGoogle Scholar
  33. 33.
    Smith FG, Perkins GD, Gates S, et al (2012) The effect of Intravenous beta-2 agonist therapy on clinical outcomes in the acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet (in press)Google Scholar
  34. 34.
    Perkins GD, Park D, Alderson D, et al (2011) The Beta Agonist Lung Injury TrIal (BALTI) —prevention trial protocol. Trials 12: 79PubMedCrossRefGoogle Scholar
  35. 35.
    Newhouse MT, Chapman KR, McCallum AL, et al (1996) Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 110: 595–603PubMedCrossRefGoogle Scholar
  36. 36.
    Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD (2002) Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 121: 846–851PubMedCrossRefGoogle Scholar
  37. 37.
    Briot R, Bayat S, Anglade D, Martiel JL, Grimbert F (2009) Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogs. Crit Care 13: R166PubMedCrossRefGoogle Scholar
  38. 38.
    Abel SJ, Finney SJ, Brett SJ, Keogh BF, Morgan CJ, Evans TW (1998) Reduced mortality in association with the acute respiratory distress syndrome (ARDS). Thorax 53: 292–294PubMedCrossRefGoogle Scholar
  39. 39.
    Stratakos G, Kalomenidis J, Routsi C, Papiris S, Roussos C (2002) Transient lactic acidosis as a side effect of inhaled salbutamol. Chest 122: 385–386PubMedCrossRefGoogle Scholar
  40. 40.
    Day NP, Phu NH, Bethell DP, et al (1996) The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 348: 219–223PubMedCrossRefGoogle Scholar
  41. 41.
    Atabai K, Ware LB, Snider ME, et al (2002) Aerosolized beta(2)-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure. Intensive Care Med 28: 705–711PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • C. R. Bassford
  • D. R. Thickett
  • G. D. Perkins

There are no affiliations available

Personalised recommendations